Floatz logo

CASPOFUNGIN

Infection

OHSU Knight Cancer InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Infection cohort.

Asset / SponsorPhaseRating
SULFAMETHOXAZOLE
Radboud University Medical Center
Phase 4A
Trimethoprim
Radboud University Medical Center
Phase 4A
Ciprofloxacin
Radboud University Medical Center
Phase 4BBB
AMDINOCILLIN
Radboud University Medical Center
Phase 4BB
Aztreonam
Liverpool Heart and Chest Hospital NHS Foundation Trust
Phase 4BB

View all 50 →

Same molecule, other indications

CASPOFUNGIN is also rated in:

fungal infectious diseaseDormant
BBB
Indicative ·
77 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
acute monocytic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →